Considerations for best practices related to sodium-glucose cotransporter-2 inhibitors and serum potassium levels

Authors

Liz Van Dril
Christine Schumacher, Advocate Aurora HealthFollow

Recommended Citation

Van Dril E, Schumacher C. Considerations for best practices related to sodium-glucose cotransporter-2 inhibitors and serum potassium levels [published correction appears in Am J Health Syst Pharm. 2022 Mar 21;79(7):601]. Am J Health Syst Pharm. 2021;78(15):1367-1368. doi:10.1093/ajhp/zxab122

Affiliations

Advocate Medical Group

Document Type

Article

PubMed ID

33764438